ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
102 announcements with these filters
Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.
Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.
Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.
Medplus Health Services reported a 7-day drug license suspension for a subsidiary store in Chhattisgarh, estimating a financial impact of ₹0.01 Crore.
Medplus Health Services reported a 5-day suspension of a drug license at a Mangalore store due to compliance issues. The expected financial impact is ₹0.03 Crore.
Medplus Health Services' subsidiary, Optival Health Solutions, faced a five-day drug license suspension at its Kapikad store due to regulatory violations. The impact is Rs 0.03 Crore.
MedPlus Health Services has filed board comments regarding a fine levied by the exchanges for non-compliance with Regulation 17(1A) of SEBI LODR Regulations, 2015.
MedPlus acquired the remaining 0.01% stake in Optival Health Solutions for Rs.1.10 Crore. This makes Optival a wholly owned subsidiary of MedPlus.
Medplus approved acquiring the 0.01% residual stake in material subsidiary Optival Health Solutions for Rs.1.10 Crore. Optival's FY26 turnover of Rs.6,816 Crore will now be fully consolidated.
Medplus Health's subsidiary received suspension notices for drug licenses at two stores. The combined financial impact is estimated at Rs 14.62 lakhs.
Medplus Health's subsidiary faces temporary drug license suspensions at two store locations in Bangalore and Pune, resulting in an estimated financial impact of Rs 0.15 Crore.
MedPlus's subsidiary faces a 7-day drug license suspension at a Maharashtra store, with an estimated financial impact of Rs 0.0175 Crore.
Alka Ajit Rangnekar, an immediate relative of a director, acquired 3,725 equity shares via off-market transfer. The transaction value amounts to approximately ₹0.24 Crore.
The Drugs Control Administration suspended the drug license of Medplus's subsidiary, Optival Health Solutions, for five days. The financial impact of this suspension is ₹0.02 Crore.
Medplus Health reported temporary drug license suspensions at three pharmacy stores, with a financial impact of ₹0.07 Crore. A prior suspension in Pune was stayed.
Medplus Health Services reported 7-day drug license suspensions for four stores across three states. The estimated financial impact of these operational disruptions is ₹0.09 Crore.
Medplus Health Services reported drug license suspensions for three of its subsidiary's stores due to regulatory violations, with an estimated financial impact of ₹0.06 Crore.
Catalyst Trusteeship Limited filed a SAST Reg 29(1) disclosure regarding the creation of a pledge on 62,51,066 equity shares of MedPlus Health Services Limited.
ICICI Prudential Mutual Fund increased its stake in Medplus Health Services Ltd by acquiring 25,29,352 shares from the open market.
MedPlus Health Services Limited held its 20th Annual General Meeting on August 17, 2026, via video conferencing to transact ordinary and special business.
Medplus Health Services' subsidiary, Optival Health Solutions, received a 2-day drug license suspension at a specific store for minor regulatory non-compliance.
Medplus Health Services' subsidiary, Optival Health Solutions, faces temporary drug license suspensions for four stores in Karnataka due to regulatory non-compliance.
MedPlus Health Services reported a 7-day drug license suspension for a subsidiary store in Andhra Pradesh due to regulatory non-compliance. The financial impact is ₹0.03 Crore.
Medplus Health Services' subsidiary, Optival Health Solutions, faces temporary drug license suspensions for two stores. The estimated financial impact is Rs 0.03 Crore.
Medplus Health Services reported a 25-day drug license suspension for its Latur store, with an estimated financial impact of Rs 0.11 Crore.
Medplus Health Services' subsidiary, Optival Health Solutions, faced a two-day drug license suspension at a Karnataka store. The regulatory action impacts operations by Rs 0.0071 Crore.
MedPlus's subsidiary, Optival Health Solutions, received a two-day drug license suspension for a store in Karnataka. The potential revenue impact is Rs 0.0071 Crore.
Medplus Health's subsidiary, Optival Health Solutions, received a 5-day suspension of its drug license at a Hanamkonda store due to regulatory violations. The financial impact is negligible.
Medplus Health Services Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b). This is for the period ending June 30, 2026.
Catalyst Trusteeship Limited reported the creation of a pledge over 49,00,000 equity shares of Medplus Health Services Limited. This disclosure pertains to debenture trustee arrangements.